|
시장보고서
상품코드
2016379
심방세동 치료 시장 보고서 : 질환 유형, 치료법, 최종사용자, 지역별(2026-2034년)Atrial Fibrillation Treatment Market Report by Disorder Type, Treatment Type, End-User, and Region 2026-2034 |
||||||
세계의 심방세동 치료 시장 규모는 2025년에 95억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 212억 달러에 달하며, 2026-2034년에 CAGR 9.06%로 성장할 것으로 예측하고 있습니다.
심방세동(AFib)은 불규칙하고 빠른 심장 박동을 동반하는 심장 질환으로 뇌졸중, 심부전 및 기타 심장 관련 합병증의 위험을 증가시킵니다. 이 상태에서는 심장의 윗부분(심방)이 불규칙하게 뛰고 아랫부분(심실)과의 협응력을 잃어 심계항진, 숨가쁨, 피로감을 유발합니다. 또한 혈전 형성을 유발하여 다른 장기로의 혈류를 방해할 수 있습니다. 심방세동의 주요 유형에는 발작성, 지속성, 장기 지속성, 지속성 심방세동이 있으며, 약물이나 심장의 전기적 자극을 조절하는 다른 치료법으로 치료할 수 있습니다.
심혈관 질환(CVD) 유병률의 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 이러한 질환은 노년층과 당뇨병, 고혈압, 심혈관 질환(CVD) 등 다른 질환을 앓고 있는 사람들에게서 많이 발생합니다. 여기에 더해 전 세계에서 꾸준히 증가하고 있는 노인 인구가 시장 성장을 촉진하고 있습니다. 또한 최소침습(MI) 수술에 대한 선호도가 높아지면서 소형 수술 기기, 임플란트 수술, 원격 간호에 대한 수요에도 긍정적인 영향을 미치고 있습니다. 또한 손상된 심장 조직을 제거하기 위한 카테터 절제 장치 개발, 혁신적인 매핑 및 기록 시스템과 같은 다양한 기술 발전도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 기타 의료 인프라 개선과 의학 분야의 광범위한 연구개발(R&D) 활동 등도 시장을 더욱 견인할 것으로 예상됩니다.
이 보고서에서 답변하는 주요 질문:
- 지금까지의 세계 심방세동 치료제 시장의 동향은 어떠했으며, 향후 수년간 어떻게 변화하는가?
- COVID-19는 세계 심방세동 치료 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 질병 유형별 시장 현황은?
- 치료법별 시장 현황은?
- 최종사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 이 산업의 밸류체인에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계 심방세동 치료 시장의 구조는 무엇이며, 주요 기업은 어디인가?
- 이 업계의 경쟁은 얼마나 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 심방세동 치료 시장
제6장 시장 내역 : 질환 유형별
제7장 시장 내역 : 치료 유형별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 경쟁 구도
KSA 26.05.07The global atrial fibrillation treatment market size reached USD 9.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 21.2 Billion by 2034, exhibiting a growth rate (CAGR) of 9.06% during 2026-2034.
Atrial fibrillation (AFib) refers to a cardiac condition with irregular and rapid heart rate that increases the risks of stroke, heart failure and other heart-related complications. In this condition, the upper (atrial) chambers beat irregularly and out of coordination with the lower (ventricle) chambers of the heart, thereby causing heart palpitations, shortness of breath and fatigue. It can also lead to the development of blood clots that may disrupt the blood flow to other organs. The main types of AFib include paroxysmal, persistent, long-term persistent, and permanent AFib that can be treated with medications and other interventions to adjust the heart's electrical impulses.
The rising prevalence of cardiovascular diseases (CVDs) is one of the key factors driving the growth of the market. Such disorders are highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, hypertension and cardiovascular diseases (CVDs). This, along with the steadily increasing geriatric population across the globe, is providing a boost to the market growth. Furthermore, the increasing preference for minimally invasive (MI) surgical procedures is also creating a positive impact on the demand for miniaturized surgical devices, implant surgeries and remote nursing. Additionally, various technological advancements, such as the development of catheter ablation devices to remove damaged heart tissues and innovative mapping and recording systems, is acting as another growth-inducing factor. Other factors, including improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global atrial fibrillation treatment market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on disorder type, treatment type and end-user.
Breakup by Disorder Type:
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation
- Permanent Atrial Fibrillation
- Others
Breakup by Treatment Type:
- Medical Procedures
- Surgical Procedures
- Maze Surgery
- Catheter Ablation
- Non-Surgical Procedures
- Electric Cardioversion
- Diagnostic Catheters
- Mapping and Recording Systems
- Cardiac Monitors
- Access Devices
- Left Atrial Appendage and Closure Devices
- Intracardiac Echocardiography (ICE) Systems
- Medication
- Anticoagulants
- Anti-Arrhythmics
Breakup by End-User:
- Hospitals
- Cardiac Labs
- Ambulatory Surgical Centers
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Atricure Inc., Biotronik, Boston Scientific Corporation, Cardiofocus Inc., Hansen Medical Inc. (Auris Health), Johnson & Johnson, Siemens Healthineers, Stereotaxis Inc., etc.
Key Questions Answered in This Report:
- How has the global atrial fibrillation treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global atrial fibrillation treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the disorder type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global atrial fibrillation treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Atrial Fibrillation Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Disorder Type
- 6.1 Paroxysmal Atrial Fibrillation
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Persistent Atrial Fibrillation
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Permanent Atrial Fibrillation
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Treatment Type
- 7.1 Medical Procedures
- 7.1.1 Market Trends
- 7.1.2 Surgical Procedures
- 7.1.2.1 Maze Surgery
- 7.1.2.2 Catheter Ablation
- 7.1.3 Non-Surgical Devices
- 7.1.3.1 Electric Cardioversion
- 7.1.3.2 Diagnostic Catheters
- 7.1.3.3 Mapping and Recording Systems
- 7.1.3.4 Cardiac Monitors
- 7.1.3.5 Access Devices
- 7.1.3.6 Left Atrial Appendage and Closure Devices
- 7.1.3.7 Intracardiac Echocardiography (ICE) Systems
- 7.1.4 Market Forecast
- 7.2 Medications
- 7.2.1 Market Trends
- 7.2.2 Drug Class
- 7.2.2.1 Anticoagulants
- 7.2.2.2 Anti-Arrhythmics
- 7.2.3 Market Forecast
8 Market Breakup by End-User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Cardiac Labs
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Ambulatory Surgical Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Atricure Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Biotronik
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Boston Scientific Corporation
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 SWOT Analysis
- 13.3.5 Cardiofocus Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.6 Hansen Medical Inc. (Auris Health)
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 Johnson & Johnson
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Siemens Healthineers
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.9 Stereotaxis Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.1 Abbott Laboratories
